Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Get Free Report) VP Robert E. Waltermire sold 14,113 shares of the stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $341.32, for a total value of $4,817,049.16. Following the sale, the vice president now directly owns 3,728 shares in the company, valued at $1,272,440.96. This trade represents a 79.10 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website.
Madrigal Pharmaceuticals Stock Performance
MDGL stock traded down $9.15 during midday trading on Tuesday, reaching $320.01. The stock had a trading volume of 270,231 shares, compared to its average volume of 433,031. The firm has a fifty day simple moving average of $324.88 and a two-hundred day simple moving average of $288.52. Madrigal Pharmaceuticals, Inc. has a 52-week low of $189.00 and a 52-week high of $377.46. The company has a debt-to-equity ratio of 0.15, a quick ratio of 5.93 and a current ratio of 5.98. The stock has a market cap of $7.07 billion, a PE ratio of -12.70 and a beta of -0.41.
Madrigal Pharmaceuticals (NASDAQ:MDGL - Get Free Report) last issued its earnings results on Wednesday, February 26th. The biopharmaceutical company reported ($2.71) EPS for the quarter, beating analysts' consensus estimates of ($4.32) by $1.61. The firm had revenue of $103.32 million during the quarter, compared to analysts' expectations of $97.81 million. As a group, equities research analysts anticipate that Madrigal Pharmaceuticals, Inc. will post -23.47 EPS for the current year.
Institutional Trading of Madrigal Pharmaceuticals
A number of institutional investors and hedge funds have recently modified their holdings of MDGL. Nisa Investment Advisors LLC boosted its holdings in Madrigal Pharmaceuticals by 47.6% in the 3rd quarter. Nisa Investment Advisors LLC now owns 211 shares of the biopharmaceutical company's stock worth $45,000 after buying an additional 68 shares during the last quarter. Kohmann Bosshard Financial Services LLC acquired a new stake in shares of Madrigal Pharmaceuticals in the fourth quarter worth approximately $70,000. Quest Partners LLC boosted its stake in shares of Madrigal Pharmaceuticals by 172.8% in the third quarter. Quest Partners LLC now owns 581 shares of the biopharmaceutical company's stock worth $123,000 after acquiring an additional 368 shares during the last quarter. GF Fund Management CO. LTD. purchased a new stake in shares of Madrigal Pharmaceuticals during the fourth quarter worth approximately $141,000. Finally, BI Asset Management Fondsmaeglerselskab A S acquired a new stake in Madrigal Pharmaceuticals during the 4th quarter worth $164,000. Hedge funds and other institutional investors own 98.50% of the company's stock.
Analysts Set New Price Targets
Several equities analysts have issued reports on MDGL shares. Cantor Fitzgerald reiterated a "neutral" rating on shares of Madrigal Pharmaceuticals in a research note on Wednesday, November 20th. JMP Securities reaffirmed a "market outperform" rating and issued a $427.00 price objective on shares of Madrigal Pharmaceuticals in a research report on Friday, January 10th. HC Wainwright increased their target price on shares of Madrigal Pharmaceuticals from $400.00 to $405.00 and gave the company a "buy" rating in a research report on Thursday, February 27th. B. Riley upgraded shares of Madrigal Pharmaceuticals from a "hold" rating to a "strong-buy" rating and raised their target price for the company from $236.00 to $422.00 in a research note on Thursday, February 27th. Finally, Citigroup upped their price target on Madrigal Pharmaceuticals from $378.00 to $469.00 and gave the stock a "buy" rating in a research report on Thursday, February 27th. Two analysts have rated the stock with a sell rating, one has issued a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $375.75.
Check Out Our Latest Research Report on Madrigal Pharmaceuticals
About Madrigal Pharmaceuticals
(
Get Free Report)
Madrigal Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH.
See Also
Before you consider Madrigal Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Madrigal Pharmaceuticals wasn't on the list.
While Madrigal Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
